08:11:20 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



Imagin Medical Inc
Symbol IME
Shares Issued 127,124,738
Close 2018-06-20 C$ 0.25
Market Cap C$ 31,781,185
Recent Sedar Documents

Imagin Medical hires Kilmer Lucas for IR services

2018-06-21 10:54 ET - News Release

Mr. Jim Hutchens reports

IMAGIN ENGAGES KILMER LUCAS FOR CROSS-BORDER INVESTOR RELATIONS

Imagin Medical Inc. has engaged Kilmer Lucas Inc. to provide the company with select U.S. and Canadian investor relations and strategic advisory services.

Employing an outsourced in-house partnership model, Kilmer Lucas designs and executes customized investor relations programs for medical device, drug development, cell therapy, diagnostics and health care services companies.

"As we continue to gain momentum, our product development activities escalate and we begin to execute other key facets of our growth strategy. We are confident that Kilmer Lucas is the right partner to help us communicate our progress to a broader investor audience in both the U.S. and Canada," said Jim Hutchens, Imagin's president and chief executive officer.

"Imagin's senior management team has a strong track record of accomplishment in the global medical device industry," commented Stephen Kilmer, founder and president of Kilmer Lucas. "That, combined with the company's positioning at the forefront of the next wave in medical imaging technology, provides the foundation for a great investment story and we are excited that Imagin has chosen us to help tell it. Through the provision of a full range of IR and strategic advisory services, our primary goals will be to assist Imagin in achieving a fair and sustainable market valuation, and to enhance the reputation that it carries in the minds of its various stakeholders, including investors, analysts and members of the media."

About Imagin Medical Inc.

Imagin Medical is developing imaging solutions for the early detection of cancer during minimally invasive surgeries. The company believes it will radically improve the way physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth-most prevalent in the United States, and the most costly cancer to treat due to a greater-than-50-per-cent recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.